Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 7, 2005 Brian Gorman	Merck's Tricky Sell A vaccine for human papillomavirus clears scientific hurdles, but marketing could prove its biggest obstacle.
The Motley Fool February 28, 2008 Brian Lawler	Third Wave Making Tiny Ripples Small molecular-diagnostics developer Third Wave Technologies could be poised for big returns.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
The Motley Fool January 31, 2007 Brian Gorman	Merck's Special Interest Merck is likely to succeed in getting states to mandate HPV vaccination. Still, investors shouldn't necessarily bet everything on Gardasil.
The Motley Fool November 6, 2007 Brian Orelli	Getting Vaccinated Alongside Mom Merck presents data supporting use of its HPV vaccine in older women. The drugmaker may have a tough marketing job ahead of it.
The Motley Fool May 8, 2009 Brian Orelli	Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot.
The Motley Fool July 20, 2007 Brian Lawler	Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck.
Pharmaceutical Executive May 1, 2006 Joanna Breitstein	Cervical Cancer: Endagered Species Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer with new HPV vaccines. Now that the science is in order, Merck and GSK face several important challenges in conditioning the market.
InternetNews August 5, 2010	Google Wave Washes Out Google Wave, the technology once heralded as a replacement for email, IM and other forms of Internet-based office collaboration, has been sunk.
The Motley Fool November 13, 2008 Brian Orelli	Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men.
Nursing October 2010 Linda Schiech	HPV-related cancer: An equal opportunity danger Although many people know that HPV infections are the leading cause of cervical cancer, they might be surprised to learn that HPV is also associated with other kinds of cancer, including cancers of the head and neck, and anal and penile cancers.
Salon.com July 24, 2000 Arthur Allen	Foil-wrapped folly What's wrong with requiring condom wrappers to carry a warning about a cancer-causing virus? Second of two parts.
The Motley Fool April 7, 2005 Brian Gorman	Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments.
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
Managed Care September 2006 Thomas Morrow	Remarkable Work Went Into Designing the New HPV Vaccine The recently approved human papillomavirus vaccine is a prime example of how science is beating back the advance of old diseases.
The Motley Fool December 18, 2007 Brian Lawler	Cervarix Won't Save Glaxo Yet The FDA has another delay for this HPV vaccine. The agency has completed its review, but still has questions.
The Motley Fool July 7, 2009 Brian Orelli	Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard.
Health October 10, 2008	Cervical Cancer FAQ Signs, symptoms, prevention, and treatments are some of the topics explained here.
The Motley Fool July 1, 2008 Brian Lawler	FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix.
Nurse Practitioner June 2012 Kostas-Polston et al.	HPV & age-appropriate cervical cancer prevention for adolescents Adolescents have the highest rates of cervical disease as a result of initial human papillomavirus exposure and infection.
American Family Physician December 15, 2004	What You Should Know About Genital Warts An informative pamphlet on the condition, how one contracts it, treatment options and preventative advice.
The Motley Fool July 20, 2006 Brian Lawler	MedImmune Is Easy to Resist Despite the prospects from sales of two new vaccines, it's hard to feel better about this stock.
The Motley Fool September 10, 2009 Brian Orelli	The Vanishing Vaccine War And it had such potential to be a bloodbath.
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
The Motley Fool June 10, 2008 Brian Orelli	Third Wave's Invader Gets Invaded Hologic picks up a promising technology as the diagnostic-testing market picks up steam.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
Scientific American February 2006	To Banish a Cancer Two vaccines that are nearing approval by the Food and Drug Administration in the U.S. have demonstrated in clinical trials that they can prevent infection from the two types of the human papillomavirus (HPV) that account for up to 70 percent of cervical cancers.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
Inc. April 1, 2010	How One Entrepreneur Uses Google Wave Daniel Tenner of Woobius uses the software to collaborate with colleagues.
American Family Physician November 15, 2000	Letters to the Editor Further Discussion on the Role of Pap Smear Screening
InternetNews December 9, 2010 Sean Michael Kerner	Apache Reviving Wave as Incubator Project Abandoned by Google, Wave finds new life as a project with the Apache Software Foundation, which Novell hopes will broaden contributions and adoption of the technology.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
Chemistry World February 6, 2014 Carla Pegoraro	Catching viruses associated with cervical cancer Researchers in the UK have developed an automated bioassay that can spot the forms of the human papilloma virus most often linked with cervical cancer.
BusinessWeek August 27, 2009 Arlene Weintraub	Is Merck Overselling a Cancer Vaccine? Fresh controversies are heating up over the marketing of products to prevent cervical cancer.
AskMen.com Dave Golokhov	STD Vaccine While teens and young adults account for only a quarter of the sexually active population, they are credited with half of the new STD cases per year.
American Family Physician September 1, 2001 Jim Nuovo	New Tests for Cervical Cancer Screening Recently, a number of new technologies have been developed to improve the detection of cervical cancer and its precursors. However, there is substantial controversy about whether the new tests offer meaningful advantages over the conventional Pap smear...
BusinessWeek January 8, 2007 Arlene Weintraub	Making Her Mark At Merck Margaret McGlynn, critical to a post-Vioxx turnaround, is on a fast track.
AskMen.com	STDs On The Rise Sexually spread diseases continue to rise, government health officials said. Better screening may be the reason.
The Motley Fool February 28, 2007 Brian Lawler	Merck's Mighty Future Merck ups its 2007 financial forecast, while positive developments occur for two of its most promising new therapies.
American Family Physician June 1, 2003	Pap Smears: When Yours Is Slightly Abnormal What did my Pap smear show?... ASCUS... AGUS... LSIL... Inflammation... etc.
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
InternetNews September 29, 2009	Google Ready to Let Testers Ride 'Wave' Google's collaboration and messaging service is ready for up to 100,000 testers.
The Motley Fool June 17, 2010 Brian Orelli	Merck Needs to Get Busy While waiting for the FDA to approve the expanded age range, sales of Merck's Gardasil have gone to sleep.
Search Engine Watch October 12, 2009 Ron Jones	Google Wave 101 Check out Google's new real-time platform combining instant messaging, e-mail, document creation, and collaboration.
The Motley Fool December 5, 2008 Brian Orelli	Good Luck in 2010, Merck It's not just one problem for Merck, but a whole series of issues that have turned the company into a heap of stale drugs.
InternetNews May 19, 2010	Google Wave Now Taking All Comers In one of the first announcements coming out of Google's annual I/O conference, the Wave collaboration and communications service is now open to the general public.
Pharmaceutical Executive February 1, 2007 Beth Herskovits	Brand of the Year A first annual Brand of the Year honor goes to Gardasil, Merck's breakthrough vaccine for human papillomavirus.
CIO May 29, 2009 C.G. Lynch	Google Wave: A New Kind of Mega-Application Google's newly unveiled Wave may be called a communication and collaboration tool, but it's much more than that.
InternetNews May 28, 2009 David Needle	Is Google's Wave the Write Stuff? Google previews a new Web-based e-mail/collaboration system. Is e-mail a thing of the past?
CRM February 2010 Jessica Tsai	Google Wave Makes a Splash in CRM Google Wave isn't the first to wade into real-time collaboration, but the tsunami of buzz may drown the competition.